Baxter Ventures invests in Opsona Therapeutics Series C round

Client(s) Baxter International Inc.

Jones Day represented Baxter Ventures, as co-investor, in connection with its purchase of €33 million (US$43 million) of Series C Preferred Shares in an oversubscribed private placement by Opsona Therapeutics Limited, an innate immune drug development company. Co-investors included BB Biotech Ventures, Sunstone Capital, Amgen Ventures, and EMBL Ventures, as well as existing investors Novartis Venture Fund, Fountain Healthcare Partners, Roche Venture Fund, and Seroba Kernel Life Sciences.